Sara Viksmoen Watle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara Viksmoen Watle has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Schjøll
Oslo Metropolitan University
2 shared publications - Arnfinn Helleve
Centre for Evaluation of Public Health Measures Norwegian Institute of Public Health Oslo Norway
2 shared publications - Atle Fretheim
Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
2 shared publications - Borghild Løyland
Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway
2 shared publications - Dominique A. Caugant
Norwegian Institute of Public Health, Oslo, Norway
2 shared publications Lisbeth Meyer Næss
Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
2 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
”Why should I pay for this vaccine?” – Norwegian adolescents views on meningococcal vaccination
Background: As one of few countries in Europe, Norway does not offer vaccination against invasive meningococcal disease (IMD) as part of the National Immunization Program for Children (NIP). Instead, adolescents aged 16–19 are recommended to consider having the meningococcal ACWY conjugate vaccine (MCV4) if they participate in activities that increase the risk of IMD. Meningococcal vaccination rates in Norway are low compared to vaccines offered through the NIP. Whereas all vaccinations in the NIP are free and organized through schools or municipal health clinics, there is no uniform system in place for the meningococcal vaccine. On the contrary, both administration practices and cost of vaccination vary nationally, with some counties offering the vaccine for free, while others offer the vaccine at a cost of $40–80. The aim of this study was to explore adolescents’ awareness, knowledge, and decision-making processes related to meningococcal disease and vaccination. Methods: Using a semi-structured interview guide, we conducted 18 focus group interviews in the fall of 2022, involving a total of 126 high school seniors in Norway. The participants were asked to share their views, knowledge and experiences regarding invasive meningococcal disease and vaccination. We used NVivo 14 to facilitate the thematic analysis and a codebook analysis approach was conducted to identify themes and patterns in the data. Results: The analysis identified three central themes emerging from the discussions with the adolescents. These emphasize how information, cost, and location and guidance impact the adolescents’ decision-making and ability to get vaccinated. Conclusions: The current organization of MCV4 vaccination in Norway do not meet the needs identified by the adolescents in this study. This results in unequal access to a highly effective vaccine that protects healthy adolescents against a deadly disease. The present study highlights the need to address vaccination disparities and accessibility, as well as increasing awareness and knowledge about meningococcal disease and vaccination to ensure equal access for all adolescents.
- 30 April 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open Access”Why should I pay for this vaccine?” – Norwegian adolescents views on meningococcal vaccination
Background: As one of few countries in Europe, Norway does not offer vaccination against invasive meningococcal disease (IMD) as part of the National Immunization Program for Children (NIP). Instead, adolescents aged 16–19 are recommended to consider having the meningococcal ACWY conjugate vaccine (MCV4) if they participate in activities that increase the risk of IMD. Meningococcal vaccination rates in Norway are low compared to vaccines offered through the NIP. Whereas all vaccinations in the NIP are free and organized through schools or municipal health clinics, there is no uniform system in place for the meningococcal vaccine. On the contrary, both administration practices and cost of vaccination vary nationally, with some counties offering the vaccine for free, while others offer the vaccine at a cost of $40–80. The aim of this study was to explore adolescents’ awareness, knowledge, and decision-making processes related to meningococcal disease and vaccination. Methods: Using a semi-structured interview guide, we conducted 18 focus group interviews in the fall of 2022, involving a total of 126 high school seniors in Norway. The participants were asked to share their views, knowledge and experiences regarding invasive meningococcal disease and vaccination. We used NVivo 14 to facilitate the thematic analysis and a codebook analysis approach was conducted to identify themes and patterns in the data. Results: The analysis identified three central themes emerging from the discussions with the adolescents. These emphasize how information, cost, and location and guidance impact the adolescents’ decision-making and ability to get vaccinated. Conclusions: The current organization of MCV4 vaccination in Norway do not meet the needs identified by the adolescents in this study. This results in unequal access to a highly effective vaccine that protects healthy adolescents against a deadly disease. The present study highlights the need to address vaccination disparities and accessibility, as well as increasing awareness and knowledge about meningococcal disease and vaccination to ensure equal access for all adolescents.
- Open Access
Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents: A Norwegian Nationwide Register-Based Study
Background: Vaccination of older adolescents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in the spring of 2021 and continued with younger adolescents throughout the summer and fall. We assessed risks of adverse events following immunization (AEFI) in adolescents aged 12–19 years following SARS-CoV-2 vaccination with a messenger RNA (mRNA) vaccine in Norway. Materials and Methods: The study sample included 496,432 adolescents born in 2002–2009, residing in Norway, and unvaccinated against SARS-CoV-2 at the beginning of the age-specific waves of vaccination in 2021. The exposures under study were first- and second-dose SARS-CoV-2 mRNA vaccinations vs. no dose. We applied Poisson regression and self-controlled case series (SCCS) analysis to estimate incidence rate ratios (IRRs) of 17 preselected outcomes, with associated 95% confidence intervals (CIs), between vaccinated and unvaccinated subjects using predefined post-vaccination risk windows. Results: Most outcome-specific numbers of cases were low. There were no statistically significant associations between first-dose vaccination and any of the outcomes. In the main Poisson regression, second-dose vaccination was associated with increased risks of anaphylactic reaction (adjusted IRR [aIRR]: 10.05; 95% CI: 1.22–82.74), lymphadenopathy (aIRR: 2.33; 95% CI: 1.46–3.72), and myocarditis and pericarditis (aIRR: 5.27; 95% CI: 1.98–14.05). We also observed increased incidence of acute appendicitis outside the 14-day risk window. When expanding the risk window to 42 days in a post-hoc analysis, there was increased incidence of acute appendicitis following both first-dose vaccination (aIRR: 1.39; 95% CI: 1.09–1.78) and second-dose vaccination (aIRR: 1.43; 95% CI: 1.07–1.91). Results of the SCCS analysis were similar to the Poisson regression. Conclusions: In general, potential AEFI were rare among adolescents. We found increased risks of anaphylactic reaction, lymphadenopathy, and myocarditis and pericarditis following second-dose vaccination. There were also indications of increased acute appendicitis risk when applying longer risk windows.
Open AccessAdverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents: A Norwegian Nationwide Register-Based Study
Background: Vaccination of older adolescents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in the spring of 2021 and continued with younger adolescents throughout the summer and fall. We assessed risks of adverse events following immunization (AEFI) in adolescents aged 12–19 years following SARS-CoV-2 vaccination with a messenger RNA (mRNA) vaccine in Norway. Materials and Methods: The study sample included 496,432 adolescents born in 2002–2009, residing in Norway, and unvaccinated against SARS-CoV-2 at the beginning of the age-specific waves of vaccination in 2021. The exposures under study were first- and second-dose SARS-CoV-2 mRNA vaccinations vs. no dose. We applied Poisson regression and self-controlled case series (SCCS) analysis to estimate incidence rate ratios (IRRs) of 17 preselected outcomes, with associated 95% confidence intervals (CIs), between vaccinated and unvaccinated subjects using predefined post-vaccination risk windows. Results: Most outcome-specific numbers of cases were low. There were no statistically significant associations between first-dose vaccination and any of the outcomes. In the main Poisson regression, second-dose vaccination was associated with increased risks of anaphylactic reaction (adjusted IRR [aIRR]: 10.05; 95% CI: 1.22–82.74), lymphadenopathy (aIRR: 2.33; 95% CI: 1.46–3.72), and myocarditis and pericarditis (aIRR: 5.27; 95% CI: 1.98–14.05). We also observed increased incidence of acute appendicitis outside the 14-day risk window. When expanding the risk window to 42 days in a post-hoc analysis, there was increased incidence of acute appendicitis following both first-dose vaccination (aIRR: 1.39; 95% CI: 1.09–1.78) and second-dose vaccination (aIRR: 1.43; 95% CI: 1.07–1.91). Results of the SCCS analysis were similar to the Poisson regression. Conclusions: In general, potential AEFI were rare among adolescents. We found increased risks of anaphylactic reaction, lymphadenopathy, and myocarditis and pericarditis following second-dose vaccination. There were also indications of increased acute appendicitis risk when applying longer risk windows.
- Open Access
- 6 April 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 131, 130-139
Invasive meningococcal disease in Norway in the two decades before the COVID-19 pandemic
- 6 April 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 131, 130-139
Open AccessInvasive meningococcal disease in Norway in the two decades before the COVID-19 pandemic
- Open Access
Relationship between teaching modality and COVID-19, well-being, and teaching satisfaction (Campus & Corona): a cohort study among students in higher education
Background: After lock-down during the first wave of the COVID-19 pandemic, higher education institutions globally struggled to balance the need for infection control and educational requirements as they prepared to reopen. A particularly difficult choice was whether to offer for in-person or online teaching, since there was little or no empirical research to inform this decision. Norwegian universities and university colleges opted for a hybrid model when they reopened for the autumn semester, with some students offered more in-person teaching than others. This gave us an opportunity to study the association between different teaching modalities and COVID-19 risk, quality of life (subjective well-being), and teaching satisfaction. Methods: We conducted a prospective, observational cohort study among students in higher education institutions in Norway. Participants were surveyed biweekly from September to December in 2020. Findings: 26 754 students from 14 higher education institutions provided data to our analyses. Our best estimate for the association between two weeks of in-person teaching and COVID-19 risk was −22% (95% CI −77% to 33%), compared to online teaching. Quality of life was positively associated with in-person teaching (3% relative risk difference; 95% CI 2% to 4%), as was teaching satisfaction (10%; 95% CI 8% to 11%). Interpretation: The association between COVID-19 infection and teaching modality was highly uncertain. Shifting from in-person to online teaching seems to have a negative impact on the well-being of students in higher education. Funding: None.
Open AccessRelationship between teaching modality and COVID-19, well-being, and teaching satisfaction (Campus & Corona): a cohort study among students in higher education
Background: After lock-down during the first wave of the COVID-19 pandemic, higher education institutions globally struggled to balance the need for infection control and educational requirements as they prepared to reopen. A particularly difficult choice was whether to offer for in-person or online teaching, since there was little or no empirical research to inform this decision. Norwegian universities and university colleges opted for a hybrid model when they reopened for the autumn semester, with some students offered more in-person teaching than others. This gave us an opportunity to study the association between different teaching modalities and COVID-19 risk, quality of life (subjective well-being), and teaching satisfaction. Methods: We conducted a prospective, observational cohort study among students in higher education institutions in Norway. Participants were surveyed biweekly from September to December in 2020. Findings: 26 754 students from 14 higher education institutions provided data to our analyses. Our best estimate for the association between two weeks of in-person teaching and COVID-19 risk was −22% (95% CI −77% to 33%), compared to online teaching. Quality of life was positively associated with in-person teaching (3% relative risk difference; 95% CI 2% to 4%), as was teaching satisfaction (10%; 95% CI 8% to 11%). Interpretation: The association between COVID-19 infection and teaching modality was highly uncertain. Shifting from in-person to online teaching seems to have a negative impact on the well-being of students in higher education. Funding: None.
- Open Access
- 25 February 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (8) , 2777-2787
Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended for teenagers with out-of-pocket payment. The teenagers are usually vaccinated through the school health service at age 18. This study aimed to estimate costs and health gains of introducing MCV4 to Norwegian teenagers through the national immunization program (NIP). A Markov model was used to analyze the cost-effectiveness of universal MCV4 vaccination of either 15-year-olds or 18-years-olds. Occurrences of IMD were simulated from 15 until 23 years of age. Costs were estimated from a healthcare perspective. Sensitivity analyses evaluated the impact of vaccine price, vaccination uptake, IMD incidence and discount rate. Compared to today’s practice of vaccinating 18-year-olds with out-of-pocket payment, introducing MCV4 to 15-year-olds in a NIP-setting, with 90% vaccine uptake and 50% rebate on vaccine price, prevented 3.2 hospitalizations, 0.20 sequelae and 0.47 deaths among 15–23-year-olds, annually. Total costs were reduced by €30,000 and 9.7 quality-adjusted life-years (QALYs) were gained per birth cohort. The probability of cost-effectiveness was 99.0%, assuming a willingness-to-pay threshold of €86,000/QALY for severe diseases in Norway. Cost-effectiveness was highly dependent on vaccine price. Vaccination of 18-year-olds in a NIP-setting was also cost-effective, but less than NIP-vaccination of 15-year-olds. Introduction of MCV4 to the 15-year-olds in the Norwegian NIP is likely to be cost-effective given a rebate on the vaccine price.
- 25 February 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (8) , 2777-2787
Open AccessCost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended for teenagers with out-of-pocket payment. The teenagers are usually vaccinated through the school health service at age 18. This study aimed to estimate costs and health gains of introducing MCV4 to Norwegian teenagers through the national immunization program (NIP). A Markov model was used to analyze the cost-effectiveness of universal MCV4 vaccination of either 15-year-olds or 18-years-olds. Occurrences of IMD were simulated from 15 until 23 years of age. Costs were estimated from a healthcare perspective. Sensitivity analyses evaluated the impact of vaccine price, vaccination uptake, IMD incidence and discount rate. Compared to today’s practice of vaccinating 18-year-olds with out-of-pocket payment, introducing MCV4 to 15-year-olds in a NIP-setting, with 90% vaccine uptake and 50% rebate on vaccine price, prevented 3.2 hospitalizations, 0.20 sequelae and 0.47 deaths among 15–23-year-olds, annually. Total costs were reduced by €30,000 and 9.7 quality-adjusted life-years (QALYs) were gained per birth cohort. The probability of cost-effectiveness was 99.0%, assuming a willingness-to-pay threshold of €86,000/QALY for severe diseases in Norway. Cost-effectiveness was highly dependent on vaccine price. Vaccination of 18-year-olds in a NIP-setting was also cost-effective, but less than NIP-vaccination of 15-year-olds. Introduction of MCV4 to the 15-year-olds in the Norwegian NIP is likely to be cost-effective given a rebate on the vaccine price.
- Open Access
Relationship between In-person Instruction and COVID-19 incidence among University Students: A Prospective Cohort Study
Whether university teaching on campus with infection control measures in place is associated with higher risk of COVID-19 than online instruction, is unknown. We will assess this by conducting repeated surveys among students at universities and university colleges in Norway, where some instruction is given in-person, and some is provided online (hybrid model). We will ask about the students’ COVID-19 status, and how much in-person and online instruction they are getting. We will estimate the association between in-person instruction and COVID-19-risk using multivariate regression, controlling for likely confounders. We will also assess whether type of instruction is associated with how satisfied the students are with the instruction, their quality of life, and learning outcomes.
Open AccessRelationship between In-person Instruction and COVID-19 incidence among University Students: A Prospective Cohort Study
Whether university teaching on campus with infection control measures in place is associated with higher risk of COVID-19 than online instruction, is unknown. We will assess this by conducting repeated surveys among students at universities and university colleges in Norway, where some instruction is given in-person, and some is provided online (hybrid model). We will ask about the students’ COVID-19 status, and how much in-person and online instruction they are getting. We will estimate the association between in-person instruction and COVID-19-risk using multivariate regression, controlling for likely confounders. We will also assess whether type of instruction is associated with how satisfied the students are with the instruction, their quality of life, and learning outcomes.
- Open Access
- 31 March 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e80
Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors
Teenagers have a higher risk of invasive meningococcal disease (IMD) than the general population. This cross-sectional study aimed to characterise strains of Neisseria meningitidis circulating among Norwegian teenagers and to assess risk factors for meningococcal carriage. Oropharyngeal swabs were collected from secondary-school students in southeastern Norway in 2018–2019. Meningococcal isolates were characterised using whole genome sequencing. Risk factors for meningococcal carriage were assessed from questionnaire data. Samples were obtained from 2296 12–24-year-olds (majority 13–19-year-olds). N. meningitidis was identified in 167 (7.3%) individuals. The highest carriage rate was found among 18-year-olds (16.4%). Most carriage isolates were capsule null (40.1%) or genogroup Y (33.5%). Clonal complexes cc23 (35.9%) and cc198 (32.3%) dominated and 38.9% of carriage strains were similar to invasive strains currently causing IMD in Norway. Use of Swedish snus (smokeless tobacco) (OR 1.56, 95% CI 1.07–2.27), kissing >two persons/month (OR 2.76, 95% CI 1.49–5.10) and partying >10 times/3months (OR 3.50, 95% CI 1.45–8.48) were associated with carriage, while age, cigarette smoking, sharing of drinking bottles and meningococcal vaccination were not. The high meningococcal carriage rate among 18-year-olds is probably due to risk-related behaviour. Use of Swedish snus is possibly a new risk factor for meningococcal carriage. Almost 40% of circulating carriage strains have invasive potential.
- 31 March 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e80
Open AccessMeningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors
Teenagers have a higher risk of invasive meningococcal disease (IMD) than the general population. This cross-sectional study aimed to characterise strains of Neisseria meningitidis circulating among Norwegian teenagers and to assess risk factors for meningococcal carriage. Oropharyngeal swabs were collected from secondary-school students in southeastern Norway in 2018–2019. Meningococcal isolates were characterised using whole genome sequencing. Risk factors for meningococcal carriage were assessed from questionnaire data. Samples were obtained from 2296 12–24-year-olds (majority 13–19-year-olds). N. meningitidis was identified in 167 (7.3%) individuals. The highest carriage rate was found among 18-year-olds (16.4%). Most carriage isolates were capsule null (40.1%) or genogroup Y (33.5%). Clonal complexes cc23 (35.9%) and cc198 (32.3%) dominated and 38.9% of carriage strains were similar to invasive strains currently causing IMD in Norway. Use of Swedish snus (smokeless tobacco) (OR 1.56, 95% CI 1.07–2.27), kissing >two persons/month (OR 2.76, 95% CI 1.49–5.10) and partying >10 times/3months (OR 3.50, 95% CI 1.45–8.48) were associated with carriage, while age, cigarette smoking, sharing of drinking bottles and meningococcal vaccination were not. The high meningococcal carriage rate among 18-year-olds is probably due to risk-related behaviour. Use of Swedish snus is possibly a new risk factor for meningococcal carriage. Almost 40% of circulating carriage strains have invasive potential.